

Department of Pathology and Laboratory Medicine

DR. ROBERT ZHONG SEMINAR

Long COVID (LC)-Revitalize: A Precision Medicine Driven Phase III Double-Blinded, Placebo Controlled, Multi-Arm Platform Clinical Drug Trial

Douglas D. Fraser, MD, PhD, FRCPC

Professor, Clinical Scientist, GSK Chair in Clinical Pharmacology,
Department of Pediatrics, Clinical Neurological Sciences and
Physiology and Pharmacology,
Schulich School of Medicine & Dentistry,
Western University



Thursday, February 12, 2026

12:00 p.m. – 1:00 p.m.

University Hospital, Auditorium A

Learning Objectives:

1. Understand how artificial intelligence-guided proteomic analysis identified biological pathways and informed selection of repurposed treatment candidates.
2. Describe the adaptive platform trial design that allows for real-time adjustments based on interim results, including potential drug combinations, discontinuation of ineffective arms, or expansion of successful interventions across global populations.
3. Explain how precision medicine approaches can target symptom domains through patient-specific outcome measures to address disease heterogeneity across diverse international populations.



Zoom Link: <https://westernuniversity.zoom.us/j/99359798442>

“The Pathology and Laboratory Medicine Zhong Seminar is a self-approved group learning activity (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada.”



Pathology and
Laboratory Medicine



Please e-mail admin.pathology@schulich.uwo.ca if you require information in a different format or if other arrangements can make this event accessible to you. Campus Accessibility Map at www.accessibility.uwo.ca/maps.htm